داء آلزهايمر

إعداد فريق مايو كلينك
07 أكتوبر 2026

الأبحاث

يدرس باحثو مايو كلينك داء الزهايمر والاختلال المعرفي المعتدل، mild cognitive impairmentوغيرهما من الحالات التي تؤثر في الذاكرة ومهارات التفكير. كذلك يدرس الباحثون عوامل الخطر والعلامات التنبؤية وأساليب التشخيص والعلاجات المحتملة لداء الزهايمر وغيره من الحالات. اقرأ المزيد عن مجالات تركيز أبحاث داء الزهايمر في مايو كلينك من هنا.

يقع مركز أبحاث داء الزهايمر في مقرين مشتركين في مدينة روتشستر بولاية مينيسوتا ومدينة جاكسونفيل بولاية فلوريدا. وتصنف هاتان المنشأتان ضمن أكثر من 30 مركزًا لأبحاث داء الزهايمر في الولايات المتحدة المخصصة لعلاج المرض بتمويل من المعهد الوطني للشيخوخة التابع لمعاهد الصحة الوطنية. كما أن مايو كلينك من المشاركين الرئيسيين في اتحاد أريزونا لداء الزهايمر.

قد تكون لديك فرصة للمشاركة في التجارب السريرية في مايو كلينك. اقرأ المزيد عن فرص المشاركة في التجارب السريرية لداء الزهايمر في مايو كلينك من هنا.

المنشورات

راجع قائمة المنشورات التي أعدّها أطباء مايو كلينك عن داء الزهايمر على محرك البحث PubMed، وهو خدمة تقدمها المكتبة الوطنية الأمريكية للطب.

  1. Jankovic J, et al., eds. Alzheimer disease and other dementias. In: Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
  2. Alzheimer's disease fact sheet. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. Accessed Aug. 23, 2024.
  3. Livingston G, et al. Dementia prevention, intervention and care: 2024 report of the Lancet standing Commission. Lancet. 2024; doi:10.1016/S0140-6736(24)01296-0.
  4. Chen L, et al. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2022; doi:10.3389/fnagi.2022.942629.
  5. Dementia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed Aug. 23, 2024.
  6. Alzheimer's disease and related dementias. Centers for Disease Control and Prevention. https://www.cdc.gov/aging/aginginfo/alzheimers.htm. Accessed Aug. 23, 2024.
  7. What is dementia? Symptoms, types, and diagnosis. National Institute on Aging. https://www.nia.nih.gov/health/diagnosing-dementia. Accessed Aug. 23, 2024.
  8. How biomarkers help diagnose dementia. National Institute on Aging. https://www.nia.nih.gov/health/biomarkers-dementia-detection-and-research. Accessed Aug. 23, 2024.
  9. Middle-stage caregiving. Alzheimer's Association. https://www.alz.org/help-support/caregiving/stages-behaviors/middle-stage. Accessed Aug. 23, 2024.
  10. Kellerman RD, et al. Alzheimer's disease. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
  11. Ferri FF. Alzheimer disease. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
  12. Early-stage caregiving. Alzheimer's Association. https://www.alz.org/help-support/caregiving/stages-behaviors/early-stage. Accessed Aug. 23, 2024.
  13. Alzheimer's disease at a glance. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/alzheimer/ataglance. Accessed Aug. 23, 2024.
  14. Budson AE, et al. Memory Loss, Alzheimer's Disease, and Dementia. 3rd ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
  15. Care in the late stages of Alzheimer's disease. National Institute on Aging. https://www.nia.nih.gov/health/coping-late-stage-alzheimers-disease. Accessed Aug. 23, 2024.
  16. Graff-Radford J, et al. New insights into atypical Alzheimer's disease in the era of biomarkers. The Lancet. Neurology. 2021; doi:10.1016/S1474-4422(20)30440-3.
  17. Naureen Z, et al. Dietary supplements in neurological diseases and brain aging. Journal of Preventve Medicine and Hygience. 2022; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
  18. Is Alzheimer's genetic? Alzheimer's Association. https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. Accessed Aug. 23, 2024.
  19. Nimmagadda R. Allscripts EPSi. Mayo Clinic. July 17, 2024.
  20. Alzheimer's disease research centers. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-research-centers#minnesota. Accessed Aug. 23, 2024.
  21. About the Alzheimer's Consortium. Arizona Alzheimer's Consortium. https://azalz.org/about/#institutes. Accessed Aug. 23, 2024.
  22. Lewis JE, et al. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research. 2021; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
  23. Home safety. Alzheimer's Association. https://www.alz.org/help-support/caregiving/safety/home-safety. Accessed Aug. 27, 2024.
  24. Argyriou S, et al. Beyond memory impairment: The complex phenotypic landscape of Alzheimer's disease. Trends in Molecular Medicine. 2024; doi:10.1016/j.molmed.2024.04.016.
  25. Grant WB, et al. Diet's role in modifying risk of Alzheimer's disease: History and present understanding. Journal of Alzheimer's Disease. 2023; doi:10.3233/JAD-230418.
  26. Wolk DA, et al. Clinical features and diagnosis of Alzheimer disease. https://www.uptodate.com/contents/search. Accessed Aug. 30, 2024.
  27. Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia. 2024; doi:10.1002/alz.13859.
  28. 2024 Alzheimer's disease facts and figures. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/facts-figures. Accessed Aug. 26, 2024.
  29. Rosenberg A, et al. Multidomain interventions to prevent cognitive impairment, Alzheimer's disease and dementia: From FINGER to World-Wide FINGERS. Journal of Prevention of Alzheimer's Disease. 2020; doi:10.14283/jpad.2019.41.
  30. Huang L, et al. Mediterranean-dietary approaches to stop hypertension intervention for neurodegenerative delay (MIND) diet and cognitive function and its decline: A prospective study and meta-analysis of cohort studies. The American Journal of Clinical Nutrition. 2023; doi:10.1016/j.ajcnut.2023.04.025.
  31. Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nature Medicine. 2024; doi:10.1038/s41591-024-02931-w.
  32. Ashton NJ, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology. 2024; doi:10.1001/jamaneurol.2023.5319.
  33. Palmqvist S, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024; doi:10.1001/jama.2024.13855.
  34. Leqembi (approval letter). Biologic License Application 761269. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269. Accessed Sept. 5, 2024.
  35. Liu E, et al. Updates in Alzheimer's disease: From basic research to diagnosis and therapies. Translational Neurodegeneration. 2024; doi:10.1186/s40035-024-00432-x.
  36. Shi M, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: A focus on aducanumab and lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
  37. Lecanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
  38. Kisunla (approval letter). Biologic License Application 761248. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248. Accessed Sept. 6, 2024.
  39. Donanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
  40. Kang C. Donanemab: First approval. Drugs. 2024; doi:10.1007/s40265-024-02087-4.
  41. Serafin P, et al. Air pollution: A silent key driver of dementia. Biomedicines. 2023; doi:10.3390/biomedicines11051477.